Association of Deficiency of Coagulation Factors (Prs, Prc, ATIII) and FVL Positivity with Preeclampsia and/or Eclampsia in Pregnant Women
-
Maryam Al-E-Rasul Dehkordi
,
Akbar Soleimani
,
Ali Haji-Gholami
,
Abdolrahim Kazemi Vardanjani
,
Saeid Al-E-Rasul Dehkordi
Abstract
Background: Thrombophilia is a pathological state of increased blood coagulability. It causes problems during pregnancy including preeclampsia, stillbirth, repeated abortions, and detached pair. Out of the most prevalent factors causing inherited thrombophilia, protein S (Prs), protein C (Prc), and antithrombin III (ATIII) deficiency, and Factor V Leiden (FVL) mutation could be mentioned. This study aimed to investigate association of these parameters with preeclampsia.
Methods: In this case-control study, 142 pregnant women with preeclampsia referred to Obstetric Clinic of Hajar Hospital, southwest of Iran, were assigned to the case group after clinical laboratory tests and according to specialist point of view and 142 pregnant women with normal blood pressure were assigned to the control group. After obtaining consent and completing relevant questionnaire, a 4-cc blood sample was taken from the patients. Coagulation factors and FVL rate were measured and after 6 months patients were followed- up. Data analysis was done by SPSS software using t-test.
Results: In view of deficiency of Prs, Prc, and ATIII, no statistically significant association was observed between case and control groups (P>0.05). Statistical t-test indicated that the rate of FVL deficiency in pregnant patients with preeclampsia was significantly different from that in the control group (p=0.03). In addition, the body mass index of case group was significantly higher than that of control group prior to pregnancy (P=0.001). In case group, preeclampsia history contributed to development of current preeclampsia in contrast to control group (p<0.001). The patients of case group were followed up after 6 months in view of blood pressure and all had a normal mean blood pressure at the completion of the study.
Conclusion: Measurement of FVL deficiency could help to decrease the unpleasant complications of vascular disorders during pregnancy. But, screening test for pre-eclampsia does not seem necessary to determine the deficiency of coagulation factors, Prs, Prc, and ATIII.
Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004 Jun 17; 350(25): 2558-63.
Lockwood C, Wendel G, Committee on practice bulletins O. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol. 2011 Sep; 118(3): 730-40.
Scifres CM, Macones GA. The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction? Am J Obstet Gynecol. 2008 Oct; 199(4): 344 e1-7.
Thomas E Andreoli, Ivor Benjamin, Robert C Griggs, Edward J Wing, J Gregory Fitz. Andreoli and carpenter's cecil essentials of medicine. Student Consult Online Access. 8th ed. 2010.
Kosar A, Kasapoglu B, Kalyoncu S, Turan H, Balcik OS, Gumus EI. Treatment of adverse perinatal outcome in inherited thrombophilias: a clinical study. Blood Coagul Fibrinolysis. 2011 Jan; 22(1): 14-8.
Bates SM. Consultative hematology: the pregnant patient pregnancy loss. Hematology Am Soc Hematol Educ Program. 2010; 2010: 166-72.
Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol. 2009 Jan; 200(1): 46 e1-5.
Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001 Oct; 109(4): 369-84.
Said JM, Higgins JR, Moses EK, Walker SP, Monagle PT, Brennecke SP. Inherited thrombophilias and adverse pregnancy outcomes: a case-control study in an Australian population. Acta Obstet Gynecol Scand. 2012 Feb; 91(2): 250-5.
Greer JP, Arber DA, Glader B, List AF, Foerster J, Paraskevas F, et al. Wintrobe's clinical hematology. 13th ed. United States, Philadelphia; Wolters Kluwer Lippincott Williams & Wilkins Health: 2014.
Cunningham F, Leveno K, Bloom S, Hauth J, Rouse D, Spong C. Williams Obstetrics. 23th ed. McGraw-Hill Professional: 2009.
Cagirgan S, Donmez A, Ispahi C. Activated protein C resistance in preeclampsia. Clin Exp Obstet Gynecol. 2004; 31(1): 59-62.
Soare AM, Popa C. Deficiencies of proteins C, S and antithrombin and factor V Leiden and the risk of ischemic strokes. J Med Life. 2010 Jul-Sep; 3(3): 235-8.
Seremak-Mrozikiewicz A, Drews K, Wender-Ozegowska E, Mrozikiewicz PM. The significance of genetic polymorphisms of factor V Leiden and prothrombin in the preeclamptic Polish women. J Thromb Thrombolysis. 2010 Jul; 30(1): 97-104.
Kupferminc MJ, Rimon E, Many A, Sharon M, Lessing JB, Gamzu R. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med. 2011 Aug; 24(8): 1042-5.
Zotz RB, Sucker C, Gerhardt A. Thrombophilia in pregnancy: venous thromboembolism, fetal loss, preeclampsia, intrauterine growth restriction. Hamostaseologie. 2008 Dec; 28(5): 455-64.
Schauf B, Bohlmann MK, Wallwiener D, Abele H. [Prophylactic treatment of preeclampsia]. Gynakol Geburtshilfliche Rundsch. 2007; 47(4): 205-8.
Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007 Oct; 29(10): 787-93.
Dudding TE, Attia J. Maternal factor V Leiden and adverse pregnancy outcome: deciding whether or not to test. J Matern Fetal Neonatal Med. 2012 Jul; 25(7): 889-94.
Lin, C.C., et al., Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol, 2013. 49(2): p. 241-50.
Skrzypczak J, Rajewski M, Wirstlein P, Gozdziewicz T, Breborowicz G, Leszczynska-Gorzelak B, et al. Incidence of hereditary thrombophilia in women with pregnancy loss in multi-center studies in Poland. Ginekol Pol. 2012 May; 83(5): 330-6.
Villani M, Tiscia GL, Margaglione M, Colaizzo D, Fischetti L, Vergura P, et al. Risk of obstetric and thromboembolic complications in family members of women with previous adverse obstetric outcomes carrying common inherited thombophilias. J Thromb Haemost. 2012 Feb; 10(2): 223-8.
Klai S, Fekih-Mrissa N, Rachdi R, Gritli N. The status of thrombophilic defects and non-O blood group as risk factors for gestational vascular complications among Tunisian women. Acta Haematol. 2011; 125(3): 115-20.
Camilleri RS, Peebles D, Portmann C, Everington T, Cohen H. -455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications. Blood Coagul Fibrinolysis. 2004 Mar; 15(2): 139-47.
Lund M, Nielsen HS, Hviid TV, Steffensen R, Nyboe Andersen A, Christiansen OB. Hereditary thrombophilia and recurrent pregnancy loss: a retrospective cohort study of pregnancy outcome and obstetric complications. Hum Reprod. 2010 Dec; 25(12): 2978-84.
Pabinger I. Thrombophilia and its impact on pregnancy. Thromb Res. 2009; 123 Suppl 3: S16-21.
Rojas JC, Luna M, Rangel-Nava H, Banos D, Collados MT. [Genetic thrombophilia and markers of endothelial activation in patients with preeclampsia]. Ginecol Obstet Mex. 2010 Aug; 78(8): 401-9.
Patnaik MM, Haddad T, Morton CT. Pregnancy and thrombophilia. Expert Rev Cardiovasc Ther. 2007 Jul; 5(4): 753-65.
| Files | ||
| Issue | Vol 8, No 4 (2014) | |
| Section | Articles | |
| Keywords | ||
| Coagulation Factors Eclampsia Factor V Leiden Pre-eclampsia Thrombophilia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
